Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Serous Ovarian Cancer 1Leukemia, Myeloid, Acute 1Immunoglobulin Light-chain Amyloidosis 1Amyloidosis 1

Interventions

Cytarabine 81Azacitidine 66venetoclax 55fludarabine 34fludarabine phosphate 31Decitabine 28Cyclophosphamide 28Idarubicin 24Peripheral Blood Stem Cell Transplantation 22Filgrastim 20Granulocyte Colony-Stimulating Factor 18Busulfan 18Mitoxantrone 16Etoposide 16Whole-Body Irradiation 15Mycophenolic Acid 14Cyclosporine 14Tacrolimus 13Melphalan 13Daunorubicin 13Clofarabine 13Methotrexate 12gilteritinib 11aldesleukin 11plerixafor 10Injections 10decitabine and cedazuridine drug combination 9Gemtuzumab 9Cladribine 9quizartinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myeloid, Acute × Drug Evaluation × Clear all
NCT05682170 2024-09-19

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 1/2 Terminated
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡